1. Home
  2. TRDA vs BLND Comparison

TRDA vs BLND Comparison

Compare TRDA & BLND Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

TRDA

Entrada Therapeutics Inc.

HOLD

Current Price

$6.78

Market Cap

275.3M

Sector

Health Care

ML Signal

HOLD

Logo Blend Labs Inc.

BLND

Blend Labs Inc.

HOLD

Current Price

$1.19

Market Cap

307.5M

Sector

Technology

ML Signal

HOLD

Company Overview

Basic Information
Metric
TRDA
BLND
Founded
2016
2012
Country
United States
United States
Employees
N/A
419
Industry
Biotechnology: Pharmaceutical Preparations
EDP Services
Sector
Health Care
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
275.3M
307.5M
IPO Year
2021
2021

Fundamental Metrics

Financial Performance
Metric
TRDA
BLND
Price
$6.78
$1.19
Analyst Decision
Strong Buy
Buy
Analyst Count
3
6
Target Price
$21.00
$4.13
AVG Volume (30 Days)
265.1K
1.6M
Earning Date
05-08-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
58.33
EPS
N/A
N/A
Revenue
$25,421,000.00
$123,585,000.00
Revenue This Year
$39.97
$12.62
Revenue Next Year
$50.80
$14.00
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$5.08
$1.18
52 Week High
$16.45
$4.13

Technical Indicators

Market Signals
Indicator
TRDA
BLND
Relative Strength Index (RSI) 45.46 28.26
Support Level $6.76 $1.18
Resistance Level $7.89 $1.60
Average True Range (ATR) 0.44 0.07
MACD -0.04 -0.02
Stochastic Oscillator 34.75 3.66

Price Performance

Historical Comparison
TRDA
BLND

About TRDA Entrada Therapeutics Inc.

Entrada Therapeutics Inc is a clinical-stage biopharmaceutical company. It aims to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The company's Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the efficient intracellular delivery into a variety of organs and tissues, resulting in an improved therapeutic index and protein-based programs for the potential treatment of neuromuscular and ocular diseases, among others. Its oligonucleotide programs are in development for the potential treatment of people living with Duchenne, which are exon 44, 45, 50, and 51 skipping amenable. It has partnered to develop a clinical-stage program, VX-670, for myotonic dystrophy type 1.

About BLND Blend Labs Inc.

Blend Labs Inc is a cloud-based platform software platform that powers the digital interface between financial services firms and consumers. It supports and simplifies applications for mortgages, consumer loans, and deposit accounts. Its operating segment is Blend Platform segment which comprises a suite of products that power the entire origination process from back-end workflows to consumer experience. The key revenue for the company is generated from the Blend Platform segment. Company has it's assets in united states, India and Mexico regions.

Share on Social Networks: